TY - JOUR T1 - Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumonia JF - medRxiv DO - 10.1101/2021.02.02.21250758 SP - 2021.02.02.21250758 AU - Soledad E. González AU - Lorena Regairaz AU - Martín R. Salazar AU - Noelia S. Ferrando AU - Verónica V. González Martínez AU - Patricia M. Carrera Ramos AU - Santiago A. Pesci AU - Juan M. Vidal AU - Nicolas Kreplak AU - Elisa Estenssoro Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/03/2021.02.02.21250758.abstract N2 - Convalescent plasma administration (CPA) is widely used to treat Covid-19, but its effectiveness remains controversial. Here we report the results of an Expanded Access Program of CPA in the province of Buenos Aires, Argentina. We evaluated the relationship between the timing of CPA and 28-day mortality in 4719 hospitalized patients with COVID-19 pneumonia. Early (≤3 days from admission) CPA was associated to decreased mortality in patients in the general ward and in the Intensive Care Unit not requiring mechanical ventilation. This suggests that the favorable effect of CPA might be related both to disease acuity and to the therapeutic window.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialWe did not register our study TIMING OF CONVALESCENT PLASMA ADMINISTRATION AND 28-DAY MORTALITY FOR COVID-19 PNEUMONIA since it was an observational study and not an intervention oneFunding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Central Ethics Committee of the Ministry of Health of Buenos Aires Province (Expedient 2020-14965594). The resolution 103/2017 of the Ministry of Health of the Province of Buenos Aires establishes the obligation of registration and accreditation of all the Institutional Ethics Committees at the Central Ethics Committee of the Ministry of Health the Province of Buenos Aires; which is not associated with any institution or organization except the same Ministry, as it is the Ethics Committee of the said body, and evaluates all projects developed by institutions of the Ministry. In the protocol of the present study, the Central Ethics Committee acts as an Institutional Evaluation Committee in use of the powers provided for by Decree 3385/08 as a research project, in which the Ministry of Health of the Province of Buenos Aires acts both as sponsor and center. The Central Committee established that this observational study had an adequate risk- benefit ratio and requested the anonymization of data. The administration of convalescent plasma required signed consent from each patient or legal representative, according to CROCPD-BA regulations (Expedient 2919/2123/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available ER -